CD274 and non-small cell lung carcinoma: When discussing immune therapy in patients with NSCLC, it is important to first acknowledge the varying efficacy when used in monotherapy as only a small percentage of NSCLC patients directly benefit from PD-1/PD-L1 checkpoint inhibitors [5].